The Guillain–Barrè peptide signatures: from Zika virus to Campylobacter, and beyond

References

• Slavov SN, Otaguiri KK, Kashima S, Covas DT. Overview of Zika virus (ZIKV) infection in regards to the Brazilian epidemic. Braz J Med Biol Res. 2016;49(5):e5420.
   Web of Science ®Google Scholar
• Solomon IH, Milner DA, Folkerth RD. Neuropathology of Zika virus infection. J Neuroinfect Dis. 2016;7(2):220.
   Google Scholar
• Mecharles S, Herrmann C, Poullain P, et al. Acute myelitis due to ZIKV infection. Lancet. 2016;387(10026):1481.
   PubMed Web of Science ®Google Scholar
• Parra B, Lizarazo J, Jiménez-Arango JA, et al. Guillain-Barré syndrome associated with Zika virus infection in Colombia. N Engl J Med. 2016;375(16):1513–1523.
   PubMed Web of Science ®Google Scholar
• Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–1539.
   PubMed Web of Science ®Google Scholar
• Oehler E, Watrin L, Larre P, et al. Zika virus infection complicated by Guillain-Barré syndrome – case report, French Polynesia, December 2013. Euro Surveill. 2014;19(9):20720.
   Google Scholar
• Kandel N, Lamichhane J, Tangermannc RH, Rodiera GRM. Detecting Guillain-Barré syndrome caused by Zika virus using systems developed for polio surveillance. Bull World Health Organ. 2016;94(9):705–708.
   Web of Science ®Google Scholar
• Leis AA, Stokic DS. Zika virus and Guillain-Barre syndrome: is there sufficient evidence for causality? Front Neurol. 2016;7:170.
   PubMed Web of Science ®Google Scholar
• Afifi AK. The Landry-Guillain-Barré Strohl Syndrome 1859 to 1992 A historical perspective. J Family Community Med. 1994;1(1):30–34.
   Google Scholar
• Jasti AK, Selmi C, Sarmiento-Monroy JC, Vega DA, Anaya JM, Gershwin ME. Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment. Expert Rev Clin Immunol. 2016;12(11):1175–1189.
   PubMed Web of Science ®Google Scholar
• Blum S, McCombe PA. Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions. J Peripher Nerv Syst. 2014;19(2):88–103.
   PubMed Web of Science ®Google Scholar
• Caporale CM, Papola F, Fioroni MA, et al. Susceptibility to Guillain-Barré syndrome is associated to polymorphisms of genes. J Neuroimmunol. 2006;177(1–2):112–118.
   Web of Science ®Google Scholar
• Myhr KM, Vågnes KS, Marøy TH, Aarseth JH, Nyland HI, Vedeler CA. Interleukin-10 promoter polymorphisms in patients with Guillain-Barré syndrome. J Neuroimmunol. 2003;139(1–2):81–83.
   Web of Science ®Google Scholar
• van Sorge NM, van der Pol WL, Jansen MD, et al. Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms. J Neuroimmunol. 2005;162(1–2):157–164.
   Web of Science ®Google Scholar
• Kuijf ML, Geleijns K, Ennaji N, van Rijs W, van Doorn PA, Jacobs BC. Susceptibility to Guillain-Barré syndrome is not associated with CD1A and CD1E gene polymorphisms. J Neuroimmunol. 2008;205(1–2):110–112.
   Web of Science ®Google Scholar
• Geleijns K, Emonts M, Laman JD, et al. Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome. J Neuroimmunol. 2007;190(1–2):127–130.
   Web of Science ®Google Scholar
• Dourado ME Jr, Ferreira LC, Freire-Neto FP, Jeronimo SM. No association between FCGR2A and FCGR3A polymorphisms in Guillain-Barré Syndrome in a Brazilian population. J Neuroimmunol. 2016;298:160–164.
   Web of Science ®Google Scholar
• Hao Q, Saida T, Kuroki S, et al. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections. J Neuroimmunol. 1998;81(1–2):116–126.
   PubMed Web of Science ®Google Scholar
• Zautner AE, Johann C, Strubel A, et al. Seroprevalence of campylobacteriosis and relevant post-infectious sequelae. Eur J Clin Microbiol Infect Dis. 2014;33(6):1019–1027.
   Web of Science ®Google Scholar
• Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, et al. Mycoplasma pneumoniae triggering the Guillain-Barré syndrome: a case-control study. Ann Neurol. 2016;80(4):566–580.
   Web of Science ®Google Scholar
• Kuwahara M, Samukawa M, Ikeda T, et al. Characterization of the neurological diseases associated with Mycoplasma pneumoniae infection and anti-glycolipid antibodies. J Neurol. 2017;264(3):467–475.
   Web of Science ®Google Scholar
• Meyer Sauteur PM, Roodbol J, Hackenberg A, et al. Severe childhood Guillain-Barré syndrome associated with Mycoplasma pneumoniae infection: a case series. J Peripher Nerv Syst. 2015;20(2):72–78.
   Google Scholar
• Ang CW, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol. 2004;25(2):61–66.
   PubMed Web of Science ®Google Scholar
• Schirmer L, Worthington V, Solloch U, et al. Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome. J Neurol. 2016;263(10):2105–2113.
   Web of Science ®Google Scholar
• Nakane S, Higuchi O, Hamada Y, et al. Ganglionic acetylcholine receptor autoantibodies in patients with Guillain-Barré syndrome. J Neuroimmunol. 2016;295-296:54–59.
   Web of Science ®Google Scholar
• Komagamine T, Yuki N. Ganglioside mimicry as a cause of Guillain-Barré syndrome. CNS Neurol Disord Drug Targets. 2006;5(4):391–400.
   Google Scholar
• Meléndez-Vásquez C, Redford J, Choudhary PP, et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol. 1997;73(1–2):124–134.
   PubMed Web of Science ®Google Scholar
• Lunn MP, Muir P, Brown LJ, MacMahon EM, Gregson NA, Hughes RA. Cytomegalovirus is not associated with IgM anti-myelin-associated glycoprotein/sulphate-3-glucuronyl paragloboside antibody-associated neuropathy. Ann Neurol. 1999;46(2):267–270.
   Web of Science ®Google Scholar
• Khalili-Shirazi A, Gregson N, Gray I, Rees J, Winer J, Hughes R. Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg Psychiatry. 1999;66(3):376–379.
   Web of Science ®Google Scholar
• Shaban E, Gohh R, Knoll BM. Late-onset cytomegalovirus infection complicated by Guillain-Barre syndrome in a kidney transplant recipient: case report and review of the literature. Infection. 2016;44(2):255–258.
   Web of Science ®Google Scholar
• Alhefzi M, Aycart MA, Bueno EM, et al. Guillain-Barré syndrome associated with resistant cytomegalovirus infection after face transplantation. Transpl Infect Dis. 2016;18(2):288–292.
   Web of Science ®Google Scholar
• Steger CM, Antretter H, Höfer D. Guillain-Barré Syndrome due to CMV reactivation after cardiac transplantation. Case Rep Cardiol. 2012;2012:506290.
   Google Scholar
• Papasotiriou M, Papachristou E, Marangos M, et al. Cytomegalovirus polyradiculopathy of late onset in a young renal transplant recipient. Clin Nephrol. 2013;80(1):75–78.
   Web of Science ®Google Scholar
• Hodowanec AC, Simon DM. Late primary cytomegalovirus infection presenting with acute inflammatory demyelinating polyneuropathy in a heart transplant recipient: a case report and review of the literature. Transpl Infect Dis. 2012;14(5):E116–E120.
   Web of Science ®Google Scholar
• Pollak-Christian E, Lee KS. Importance of diagnostic work-up of Guillain-Barré syndrome in pregnancy. BMJ Case Rep. 2016;2016:bcr2016216826.
   Google Scholar
• Lupo J, Germi R, Jean D, et al. Guillain-Barré syndrome and cytomegalovirus infection during pregnancy. J Clin Virol. 2016;79:74–76.
   Web of Science ®Google Scholar
• Orlikowski D, Porcher R, Sivadon-Tardy V, et al. Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis. 2011;52(7):837–844.
   Web of Science ®Google Scholar
• Bitan M, Or R, Shapira MY, et al. Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation. Clin Infect Dis. 2004;39(7):1076–1078.
   Web of Science ®Google Scholar
• Kennedy M, Apostolova M. A rare case of infectious mononucleosis complicated by Guillain-Barre syndrome. Neurol Int. 2013;5(2):20–22.
   Google Scholar
• Rho YI. Overlapping Guillain-Barré syndrome and Bickerstaff’s brainstem encephalitis associated with Epstein Barr virus. Korean J Pediatr. 2014;57(10):457–460.
   Google Scholar
• Communal C, Filleron A, Baron-Joly S, Salet R, Tran TA. Pediatric Miller Fisher Syndrome complicating an Epstein-Barr virus infection. Pediatr Neurol. 2016;63:73–75.
   Web of Science ®Google Scholar
• Masajtis-Zagajewska A, Muras K, Mochecka-Thoelke A, Kurnatowska I, Nowicki M. Guillain-Barré syndrome in the course of EBV infection after kidney transplantation – a case report. Ann Transplant. 2012;17(3):133–137.
   Web of Science ®Google Scholar
• Rickinson AB, Kieff E. Epstein–Barr virus. In: Knipe DM, Howley PM, editors. Fields Virology. Vol. 2. Philadelphia, PA: Lippincott, Williams & Wilkins; 2007:2655–2700.
   Google Scholar
• Capone G, Calabrò M, Lucchese G, et al. Peptide matching between Epstein-Barr virus and human proteins. Pathog Dis. 2013;69(3):205–212.
   Web of Science ®Google Scholar
• Saraya T, Kurai D, Nakagaki K, et al. Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumoniae and therapeutic implications. Front Microbiol. 2014;5:410.
   PubMed Web of Science ®Google Scholar
• Poole E, Sinclair J. Sleepless latency of human cytomegalovirus. Med Microbiol Immunol. 2015;204(3):421–429.
   Web of Science ®Google Scholar
• Jarvis M, Nelson J. HCMV: molecular basis of persistence and latency. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. (Chap. 42). Cambridge, UK: Cambridge University Press; 2007:765–779.
   Google Scholar
• Tu ZC, Gaudreau C, Blaser MJ. Mechanisms underlying Campylobacter fetus pathogenesis in humans: surface-layer protein variation in relapsing infections. J Infect Dis. 2005;191(12):2082–2089.
   Web of Science ®Google Scholar
• Lucchese G, Kanduc D. Zika virus and autoimmunity: from microcephaly to Guillain-Barré syndrome, and beyond. Autoimmun Rev. 2016;15(8):801–808.
   Web of Science ®Google Scholar
• Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360(24):2536–2543.
   PubMed Web of Science ®Google Scholar
• Magrane M, UniProt Consortium. UniProt knowledgebase: a hub of integrated protein data. Database (Oxford). 2011;2011:bar009.
   Google Scholar
• Lei JH, Tian Y, Luo HY, Chen Z, Peng F. Guillain-Barré syndrome following acute co-super-infection of hepatitis E virus and cytomegalovirus in a chronic hepatitis B virus carrier. J Med Virol. 2017;89(2):368–372.
   Web of Science ®Google Scholar
• Souayah N, Michas-Martin PA, Nasar A, et al. Guillain-Barré syndrome after Gardasil vaccination: data from vaccine adverse event reporting system 2006-2009. Vaccine. 2011;29(5):886–889.
   PubMed Web of Science ®Google Scholar
• Alcalde-Cabero E, Almazán-Isla J, García López FJ, et al. Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database. BMC Neurol. 2016;16:75.
   Web of Science ®Google Scholar
• Umapathi T, Lim CS, Ooi EE, et al. Asymptomatic dengue infection may trigger Guillain-Barré syndrome. J Peripher Nerv Syst. 2016;21(4):375–377.
   Web of Science ®Google Scholar
• Blakely PK, Kleinschmidt-DeMasters BK, Tyler KL, Irani DN. Disrupted glutamate transporter expression in the spinal cord with acute flaccid paralysis caused by West Nile virus infection. J Neuropathol Exp Neurol. 2009;68(10):1061–1072.
   Web of Science ®Google Scholar
• Vanderley Oliveira AC, da Mota LMH, dos Santos-Neto LL, et al. Occurrence of autoimmune diseases related to the vaccine against yellow fever. Autoimmune Dis. 2014;2014:473170.
   Google Scholar
• Yoshikawa T, Suzuki K, Suga S, et al. Immune response to gangliosides in a case of Guillain-Barré syndrome after varicella. Arch Dis Child. 2000;83(2):172–173.
   Web of Science ®Google Scholar
• Frank A. Immunology and Evolution of Infectious Disease. Princeton, NJ: Princeton University Press; 2002.
   Google Scholar
• Zeng W, Pagnon J, Jackson DC. The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. Mol Immunol. 2007;44(15):3724–3731.
   Web of Science ®Google Scholar
• Kanduc D. Pentapeptides as minimal functional units in cell biology and immunology. Curr Protein Pept Sci. 2013;14(2):111–120.
   PubMed Web of Science ®Google Scholar
• Chen C, Li Z, Huang H, Suzek BE, Wu CH, UniProt Consortium. A fast Peptide Match service for UniProt knowledgebase. Bioinformatics. 2013;29(21):2808–2809.
   PubMed Web of Science ®Google Scholar
• Vita R, Overton JA, Greenbaum JA, et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 2015;43(Database issue):D405–D412.
   PubMedGoogle Scholar
• Natale C, Giannini T, Lucchese A, Kanduc D. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol Cell Biol. 2000;78(6):580–585.
   PubMed Web of Science ®Google Scholar
• Kanduc D, Stufano A, Lucchese G, Kusalik A. Massive peptide sharing between viral and human proteomes. Peptides. 2008;29(10):1755–1766.
   PubMed Web of Science ®Google Scholar
• Lucchese G. Understanding neuropsychiatric diseases, analyzing the peptide sharing between infectious agents and the language-associated NMDA 2A Protein. Front Psychiatry. 2016;7:60.
   Web of Science ®Google Scholar
• Lucchese G. From toxoplasmosis to schizophrenia via NMDA dysfunction: peptide overlap between Toxoplasma gondii and N-Methyl- d-Aspartate receptors as a potential mechanistic link. Front Psychiatry. 2017;8:37.
   Web of Science ®Google Scholar
• Lucchese G, Capone G, Kanduc D. Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins. Schizophr Bull. 2014;40(2):362–375.
   PubMed Web of Science ®Google Scholar
• Lucchese G, Kanduc D. Single amino acid repeats connect viruses to neurodegeneration. Curr Drug Discov Technol. 2014;11(3):214–219.
   Google Scholar
• Lucchese G. Confronting JC virus and Homo sapiens biological signatures. Front Biosci. 2013;18:716–724.
   Web of Science ®Google Scholar
• Lucchese G. A peptide talk between JC virus and the human host: from silent infection to autoimmunity. Immunopharmacol Immunotoxicol. 2012;34(6):1067–1074.
   PubMed Web of Science ®Google Scholar
• Lucchese G, Kanduc D. Minimal immune determinants connect Zika virus, human Cytomegalovirus, and Toxoplasma gondii to microcephaly- related human proteins. Am J Reprod Immunol. 2017;77(2):e12608.
   Web of Science ®Google Scholar
• Takahashi T, Suzuki T. Role of sulfatide in normal and pathological cells and tissues. J Lipid Res. 2012;53(8):1437–1450.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Dupree JL, Ikenaka K, et al. A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. J Neurosci. 2002;22(15):6507–6514.
   PubMed Web of Science ®Google Scholar
• Piao H, Minohara M, Kawamura N, et al. Tissue binding patterns and in vitro effects of Campylobacter jejuni DNA-binding protein from starved cells. Neurochem Res. 2011;36(1):58–66.
   Web of Science ®Google Scholar
• Notturno F, Caporale CM, De Lauretis A, Uncini A. Glial fibrillary acidic protein: a marker of axonal Guillain-Barrè syndrome and outcome. Muscle Nerve. 2008;38(1):899–903.
   Web of Science ®Google Scholar
• Bolis A, Coviello S, Visigalli I, et al. Dlg1, Sec8, and Mtmr2 regulate membrane homeostasis in Schwann cell myelination. J Neurosci. 2009;29(27):8858–8870.
   Web of Science ®Google Scholar
• Robinson FL, Dixon JE. The phosphoinositide-3-phosphatase MTMR2 associates with MTMR13, a membrane-associated pseudophosphatase also mutated in type 4B Charcot-Marie-Tooth disease. J Biol Chem. 2005;280(36):31699–31707.
   Web of Science ®Google Scholar
• Nakhro K, Park JM, Hong YB, et al. SET binding factor 1 (SBF1) mutation causes Charcot-Marie-Tooth disease type 4B3. Neurology. 2013;81(2):165–173.
   Web of Science ®Google Scholar
• Firestein R, Nagy PL, Daly M, Huie P, Conti M, Cleary ML. Male infertility, impaired spermatogenesis, and azoospermia in mice deficient for the pseudophosphatase Sbf1. J Clin Invest. 2002;109(9):1165–1172.
   Web of Science ®Google Scholar
• Gupta VA, Hnia K, Smith LL, et al. Loss of catalytically inactive lipid phosphatase myotubularin-related protein 12 impairs myotubularin stability and promotes centronuclear myopathy in zebrafish. PLoS Genet. 2013;9(6):e1003583.
   Web of Science ®Google Scholar
• Bolino A, Bolis A, Previtali SC, et al. Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired spermatogenesis. J Cell Biol. 2004;167(4):711–721.
   Web of Science ®Google Scholar
• Yin PQ, Sun YY, Chen HP, Li GZ, Zhong D. Genome-wide gene expression analysis of peripheral leukocytes in relation to the male predominance of Guillain-Barre syndrome: differential gene expression between male and female patients. Int J Neurosci. 2016;126(6):531–541.
   PubMed Web of Science ®Google Scholar
• Takasaki N, Tachibana K, Ogasawara S, et al. A heterozygous mutation of GALNTL5 affects male infertility with impairment of sperm motility. Proc Natl Acad Sci U S A. 2014;111(3):1120–1125.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Yamashiro S, Yodoi J, Lloyd KO, Shiku H, Furukawa K. Expression cloning of beta 1,4 N-acetylgalactosaminyltransferase cDNAs that determine the expression of GM2 and GD2 gangliosides. J Biol Chem. 1992;267(17):12082–12089.
   Web of Science ®Google Scholar
• Foster AC, Farnsworth J, Lind GE, et al. D-Serine is a substrate for neutral amino acid transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and is transported by both subtypes in rat hippocampal astrocyte cultures. PLoS One. 2016;11(6):e0156551.
   Web of Science ®Google Scholar
• Weiss MD, Derazi S, Kilberg MS, Anderson KJ. Ontogeny and localization of the neutral amino acid transporter ASCT1 in rat brain. Brain Res Dev Brain Res. 2001;130(2):183–190.
   Google Scholar
• Takei K, Sato M, Nakamura M, Shimizu H. Longitudinally extensive transverse myelitis with anti-NMDA receptor antibodies during a systemic lupus erythematosus flare-up. BMJ Case Rep. 2015.
   Google Scholar
• Ishikawa Y, Ikeda K, Murata K, et al. Ophthalmoplegia and flaccid paraplegia in a patient with anti-NMDA receptor encephalitis: a case report and literature review. Intern Med. 2013;52(24):2811–2815.
   Web of Science ®Google Scholar
• Long JB, Rigamonti DD, Oleshansky MA, Wingfield CP, Martinez-Arizala A. Dynorphin A-induced rat spinal cord injury: evidence for excitatory amino acid involvement in a pharmacological model of ischemic spinal cord injury. J Pharmacol Exp Ther. 1994;269(1):358–366.
   PubMed Web of Science ®Google Scholar
• Wang L, Shao C, Yang C, Kang X, Zhang G. Association of anti-gangliosides antibodies and anti-CMV antibodies in Guillain-Barré syndrome. Brain Behav. 2017;7(5):e00690.
   PubMed Web of Science ®Google Scholar
• Asthana P, Vong JS, Kumar G, et al. Dissecting the role of anti-ganglioside antibodies in Guillain-Barré syndrome: an animal model approach. Mol Neurobiol. 2016;53(7):4981–4991.
   Web of Science ®Google Scholar
• Mansfield KL, Horton DL, Johnson N, et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol. 2011;92(pt 12):2821–2829.
   PubMedGoogle Scholar
• Landry ML, St George K. Laboratory diagnosis of Zika virus infection. Arch Pathol Lab Med. 2017;141(1):60–67.
   Web of Science ®Google Scholar
• Fazekas de St Groth S, Webster RG. Disquisitions of original antigenic sin. I. Evidence in man. J Exp Med. 1966;124(3):331–345.
   Web of Science ®Google Scholar
• Bardina SV, Bunduc P, Tripathi S, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017;356(6334):175–180.
   PubMed Web of Science ®Google Scholar